← All trials
NCT04435990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Apr 30, 2022
- First posted
- Jun 17, 2020
- Last posted
- Jun 17, 2020
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Inmunotek S.L.Lead sponsor
- Alergocantabria, SantanderOverall official - principal investigator
- Alergocan, TenerifeOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Centro Médico Puerto, JerezOverall official - principal investigator
- Clínica Corachan, BarcelonaOverall official - principal investigator
- Clínica IMEDOverall official - principal investigator
- Clinica Privada, Málaga.Overall official - principal investigator
- Clinica Quirón Salud, CórdobaOverall official - principal investigator
- Clínica TECMA, AlziraOverall official - principal investigator
- Clínica Virgen del Rosario, AlgecirasOverall official - principal investigator
- University Hospital Quirón Dexeus, BarcelonaOverall official - principal investigator
- Hospital POLUSA, LugoOverall official - principal investigator
- Quirón MálagaOverall official - principal investigator
- Quirón Palma de MallorcaOverall official - principal investigator
- Sanatorio Nosa Sra. Dos Ollos Grandes, LugoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.